4月4日，吴德沛教授课题组在《LeukemiaResearch》上发表题为“Comparison of outcomes in mixed phenotypeacute leukemia patients treated with chemotherapy and stem cell transplantationversus chemotherapy alone”的研究论文，总结了急性杂合细胞白血病化疗和移植疗效。吴德沛教授为该文的通讯作者。

急性混合细胞白血病（MPAL）是一种比较罕见的、异质性较高的疾病，目前尚未对该病的治疗达成共识，一直是临床治疗的难点，目前暂无比较其化疗和异基因移植疗效的报道。本中心总结了十年间66例MPAL患者，通过比较仅化疗者和化疗后采用异基因造血干细胞移植者，发现将异基因造血干细胞移植作为巩固治疗方案的患者生存收益，此外，处于缓解状态下行异基因移植者生存时间更长。该结果对指导临床工作和深入研究提供了依据，具有一定的临床和科研价值。

原文摘要：Theoptimal treatment approach for mixed phenotype acute leukemia (MPAL) remainsunknown, and prognostic factors for treatment outcomes need to be identified.In this study, 66 patients diagnosed with MPAL according to criteria publishedby the WHO in 2008 were retrospectively assessed to evaluate the effectivenessof treatment and identify predictive variables. Five patients died of severeinfection after the first induction chemotherapy, 29 received alloHSCT afterinduction (HSCT group), and 32 received only chemotherapy (chemotherapy group).The 3-year OS and DFS estimates for the entire cohort were 45% and 38%,respectively, and the 3-year OS differed significantly between the HSCT andchemotherapy-only groups (77% versus 16%). Using multivariate analyses, weidentified disease burden as a prognostic factor for transplantation outcome,with the 3-year OS being 80% among patients who achieved remission and only 45%among patients in cases of nonremission. Our results indicate that alloHSCTafter chemotherapy offers a survival advantage compared with chemotherapy only,and patients in remission before transplantation may experience a betteroutcome.

原文链接：http://dx.doi.org/10.1016/j.leukres.2016.04.002